- Home
- SIGA
as 11-21-2024 4:00pm EST
SIGA Technologies Inc is a commercial-stage pharmaceutical company focused on the health security market. The company's main product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by the variola virus. The company derives maximum revenue from United States.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 551.0M | IPO Year: | 1997 |
| Target Price: | N/A | AVG Volume (30 days): | 546.7K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | Dividend Payout Frequency: | N/A | |
| EPS: | 1.20 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.26 - $12.83 | Next Earning Date: | 11-07-2024 |
| Revenue: | $173,731,386 | Revenue Growth: | 399.31% |
| Revenue Growth (this year): | 16.98% | Revenue Growth (next year): | 16.49% |
Latest SIGA Technologies Inc. News
SIGA Breaking Stock News: Dive into SIGA Ticker-Specific Updates for Smart Investing
Zacks
13 hours ago
Are Investors Undervaluing Siga Technologies (SIGA) Right Now?
Simply Wall St.
7 days ago
Impressive Earnings May Not Tell The Whole Story For SIGA Technologies (NASDAQ:SIGA)
Simply Wall St.
13 days ago
SIGA Technologies Third Quarter 2024 Earnings: EPS: US$0.019 (vs US$0.006 loss in 3Q 2023)
GuruFocus.com
14 days ago
SIGA Technologies Inc (SIGA) Q3 2024 Earnings Call Highlights: Strong Procurement Orders and ...
GlobeNewswire
14 days ago
SIGA Reports Financial Results for Three and Nine Months Ended September 30, 2024
GlobeNewswire
22 days ago
SIGA to Host Business Update Call on November 7 Following Release of Third-Quarter 2024 Financial Results
Zacks
22 days ago
Siga Technologies Inc. (SIGA) Falls More Steeply Than Broader Market: What Investors Need to Know
Simply Wall St.
23 days ago
Three Undiscovered Gems With Promising Potential
Compare SIGA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SIGA SIGA Technologies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.